Mdxhealth (NASDAQ: MDXH) will release its second quarter 2026 financial results for the period ended June 30, 2026, after market close on Thursday, August 13, 2026. The company will host a results and corporate update conference call and webcast at 4:30pm ET / 22:30 CET, with live Q&A and a replay available on its website.
Loading...
Loading translation...
Positive
None.
Negative
None.
Market Context
The comparable earnings-date announcement was followed by a 0.98% 24-hour move, while current short ...
Analysis
The comparable earnings-date announcement was followed by a 0.98% 24-hour move, while current short positioning was categorized as low. The upcoming results add a new datapoint alongside an active financing shelf; reported results and funding disclosures remain the key comparison.
Key Figures
Reporting period:Second quarter ended June 30, 2026Results release date:August 13, 2026Conference call time:4:30pm ET / 22:30 CET+1 more
4 metrics
Reporting periodSecond quarter ended June 30, 20262Q26 financial results
Results release dateAugust 13, 2026After market close
Conference call time4:30pm ET / 22:30 CETAugust 13, 2026
Webcast access timing15 minutesBefore conference call start time
Scheduled Q1 2026 results release and conference call announcement
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
The tag-matched prior earnings-date announcement was followed by a 0.98% positive 24-hour price reaction.
Key Terms
genomic, epigenomic, exosomal, prognosis
4 terms
genomictechnical
"proprietary genomic, epigenomic, exosomal and other molecular technologies"
Relating to an organism’s genome — the complete set of DNA instructions that determine traits and biological functions — and to the study or use of that information. For investors, genomic technologies and data underpin diagnostics, targeted medicines, and personalized treatments, shaping potential market size, product timelines, and regulatory risk; think of it as reading an instruction manual to design precise medical products, which can speed innovation but also bring scientific and approval uncertainty.
epigenomictechnical
"proprietary genomic, epigenomic, exosomal and other molecular technologies"
The epigenomic describes the pattern of chemical tags and markers across a cell’s DNA that control which genes are turned on or off, like sticky notes on a recipe book guiding what gets cooked. For investors, epigenomic changes are important because they can reveal new drug targets, diagnostics, or ways to predict and treat disease, affecting a biotech’s product pipeline, regulatory path, and long-term market value.
exosomalmedical
"proprietary genomic, epigenomic, exosomal and other molecular technologies"
Describing something derived from or related to exosomes — tiny packets cells naturally release to send signals and carry molecules like proteins, RNA or lipids to other cells. For investors, “exosomal” flags technologies or products that use these biological packets for diagnostics, drug delivery or disease monitoring, which can promise more precise tests or therapies but also face scientific, manufacturing and regulatory hurdles. Think of exosomes as biological mail carriers and “exosomal” as anything that uses or studies that mail.
prognosismedical
"assist physicians with the diagnosis and prognosis of prostate cancer"
Expected course and likely outcome of a disease or medical condition, often including chances of recovery, progression, or survival. Investors look at prognosis because it helps gauge how valuable a treatment or diagnostic might be: a therapy that meaningfully improves a poor prognosis can change patient outcomes and affect future sales, regulatory interest, and market expectations. Think of it as a weather forecast for a patient’s health outlook.
Company to Host Conference Call with Live Q&A, August 13, 2026, at 4:30pm ET / 22:30 CET
IRVINE, California – July 30, 2026 (GlobeNewswire) – Mdxhealth SA (NASDAQ: MDXH), a leading precision diagnostics company, today announced it will release its financial results for the second quarter ended June 30, 2026, after market close on Thursday, August 13, 2026.
Title:
Mdxhealth Presents Second Quarter 2026 Financial Results and Corporate Update Conference Call and Webcast
Date:
August 13, 2026
Time:
4:30pm ET/ 22:30 CET
Conference Call Dial-in Details:
United States: 1-833-309-3473 Belgium: 0800 72 519 United Kingdom: 0808 101 1183
The webcast should be accessed 15 minutes prior to the conference call start time. A replay of the webcast will be available following the conclusion of the live call and will be accessible on the Company’s website.
About Mdxhealth
Mdxhealth is a leading precision diagnostics company that provides actionable molecular information to personalize patient diagnosis and treatment. The Company’s tests, based on proprietary genomic, epigenomic, exosomal and other molecular technologies, assist physicians with the diagnosis and prognosis of prostate cancer and other urologic diseases. For more information, visit mdxhealth.com and follow us on social media at: twitter.com/mdxhealth, facebook.com/mdxhealth and linkedin.com/company/mdxhealth.
When will Mdxhealth (NASDAQ: MDXH) report its Q2 2026 financial results?
Mdxhealth will report its Q2 2026 financial results on August 13, 2026, after market close. According to Mdxhealth, the results cover the quarter ended June 30, 2026, and will be followed by a conference call and webcast.
What time is the Mdxhealth (MDXH) Q2 2026 earnings conference call on August 13, 2026?
The Mdxhealth Q2 2026 earnings conference call is scheduled for 4:30pm ET / 22:30 CET on August 13, 2026. According to Mdxhealth, investors can join by phone using regional dial-ins or via a live webcast.
How can investors access the Mdxhealth (MDXH) Q2 2026 earnings webcast?
Investors can access the Mdxhealth Q2 2026 earnings webcast at https://viavid.webcasts.com/starthere.jsp?ei=1768432&tp_key=e5dee9dbef. According to Mdxhealth, the webcast should be accessed 15 minutes early, and a replay will be available on the company’s website.
What are the dial-in numbers for the Mdxhealth (MDXH) Q2 2026 earnings call?
For the Mdxhealth Q2 2026 earnings call, U.S. participants dial 1-833-309-3473, Belgium 0800 72 519, and U.K. 0808 101 1183. According to Mdxhealth, callers should reference conference ID MDX2Q26 when joining.
Will there be a replay of the Mdxhealth (MDXH) Q2 2026 earnings webcast?
Yes, a replay of the Mdxhealth Q2 2026 earnings webcast will be available after the live call. According to Mdxhealth, the replay can be accessed on the company’s website following the conclusion of the August 13, 2026 event.
What does Mdxhealth (MDXH) do as a precision diagnostics company?
Mdxhealth is a precision diagnostics company providing molecular tests to personalize diagnosis and treatment. According to Mdxhealth, its proprietary genomic, epigenomic, exosomal and other technologies support physicians in diagnosing and assessing prognosis of prostate cancer and other urologic diseases.
